Story
Moody's Downgrades Vivid Seats to Caa3, Citing Restructuring Risk
Summary
Moody's Ratings has cut the corporate family rating of Vivid Seats (Hoya Midco, LLC) to Caa3 from Caa1, pointing to a higher probability of a distressed exchange amid collapsing earnings and high leverage.
Moody's Ratings has downgraded the corporate family rating for Hoya Midco, LLC, the parent company of Vivid Seats (NASDAQ:SEAT), to Caa3 from Caa1. The ratings agency cited an increased likelihood of a balance sheet restructuring or a distressed exchange as the primary driver for the decision.
Rationale for the Downgrade
The downgrade reflects Vivid Seats' deteriorating financial position, characterized by high leverage and limited free cash flow. According to Moody's, the company has experienced sharp declines in gross order value compared to historical levels, leading to a significant drop in profitability.
Key factors highlighted by the ratings agency include:
- Moody’s-adjusted EBITDA fell to near-zero for the 12 months ending in June 2026, a stark contrast to approximately $100 million at the end of 2024.
- The agency projects that the company's adjusted leverage will remain well above 10x even with an expected stabilization in performance.
- In addition to the corporate family rating, Moody's also lowered the probability of default rating to Caa3-PD from Caa1-PD and cut the rating on its senior secured first lien term loan due 2029 to Caa3.
Financial Pressures and Liquidity
AdVivid Seats' financial obligations are straining its cash flow. The company reported $137 million in cash as of the second quarter of 2026, but faces significant annual expenses. Moody's projects the company will generate only around $5 million in free cash flow in 2026 after accounting for capitalized software development costs.
This is set against annual cash interest payments of $23 million and capital expenditures of approximately $15 million. In a recent move, Vivid Seats terminated its $100 million revolving credit facility in August 2026 and entered a new, smaller $75 million facility through its Vegas.com, LLC subsidiary, which was moved outside the company's restricted group in May 2026.
Outlook Remains Negative
Moody's maintained its negative outlook on Vivid Seats, signaling that a further downgrade is possible if conditions do not improve. The speculative grade liquidity rating remains unchanged at SGL-3.
The Caa3 rating on the senior secured term loan reflects Moody's expectation of an average family recovery rate of 50% in the event of a default.
Read next
More on Stocks
BOJ Rate Hike Nears, Pitting Japanese Financials Against Exporters
The Bank of Japan is widely expected to raise its key interest rate to a 31-year high this week, a move that is creating a sharp divide in the stock market between beneficiaries like banks and sectors facing pressure, such as exporters.
Genscript Biotech Stock Surges Over 16% on Eli Lilly AI Partnership
Shares in the Hong Kong-listed biotech firm rallied after announcing a collaboration with Eli Lilly's AI-powered drug discovery platform, a move supported by a recent capital raise focused on AI infrastructure.
Volkswagen's Seat Brand Faces Discontinuation Amid Chinese EV Pressure
Volkswagen is reportedly set to phase out its historic Spanish brand, Seat, as part of a major restructuring to combat rising competition from Chinese automakers and focus investment on its profitable, all-electric Cupra marque.
Hong Kong Biotech Sector Shows Stark Divide as Biocytogen, Genscript Post Major Gains
A small group of companies, led by Biocytogen Pharmaceuticals and Genscript Biotech, have delivered substantial one-year returns, highlighting a sharp performance gap within Hong Kong's 52-stock biotech universe where most firms remain unprofitable.